{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.00","value":"-5.3"},{"groupId":"OG001","spread":"10.93","value":"-6.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"353"},{"groupId":"OG001","value":"375"}],"units":"Participants"}],"title":"Week 4 (n=353,375)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.28","value":"-4.0"},{"groupId":"OG001","spread":"10.65","value":"-6.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"293"},{"groupId":"OG001","value":"330"}],"units":"Participants"}],"title":"Week 10 (n=293,330)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.13","value":"-3.8"},{"groupId":"OG001","spread":"11.16","value":"-6.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"273"},{"groupId":"OG001","value":"280"}],"units":"Participants"}],"title":"Week 16 (n=273,280)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.77","value":"-2.9"},{"groupId":"OG001","spread":"10.51","value":"-6.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"240"}],"units":"Participants"}],"title":"Week 22 (n=227,240)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"353"},{"groupId":"OG001","value":"375"}],"units":"Participants"}],"description":"FACIT Fatigue Subscale is a short, 13-item, easy to administer tool that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four point Likert scale (4 = not at all fatigued to 0 = very much fatigued). The total score range is from 0-52. The higher the score, the lower the fatigue level.","dispersionType":"Standard Deviation","groups":[{"description":"Participants were administered pazopanib 800 mg (2 x 400 mg tablets) orally OD continuously. Pazopanib was to be taken at least one hour before or at least two hours after a meal. Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.","id":"OG000","title":"Pazopanib 800 mg"},{"description":"Participants were administered sunitinib 50 mg orally once daily in 6-week cycles (4 weeks of treatment, followed by 2 weeks without treatment). Participants received study treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent for any other reasons.","id":"OG001","title":"Sunitinib 50 mg"}],"paramType":"MEAN","populationDescription":"Intent-to-Treat (ITT) Population. Analysis was based on the assigned randomized treatment, not on the actual treatment received/not received. Some participants were missing scores at Baseline and were excluded from the analysis. Participants missing scores at some of the other early time points were excluded from the analysis at those time points.","reportingStatus":"POSTED","timeFrame":"Baseline (predose), Day 28 of Cycles 1-4 (average of Weeks 4, 10, 16, and 22, respectively)","title":"Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale Scores at Day 28 of Cycles 1-4","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}